CSPC Hunan Jingfeng Pharmaceutical Co., Ltd. (SHE:000908)
China · Delayed Price · Currency is CNY 6.42
-0.27 (-4.04%)
Aug 24, 2026, 3:04 PM CST
SHE:000908 Revenue
CSPC Hunan Jingfeng Pharmaceutical had revenue of 94.85M CNY in the quarter ending June 30, 2026, with 13.90% growth. This brings the company's revenue in the last twelve months to 397.12M, up 0.07% year-over-year. In the year 2025, CSPC Hunan Jingfeng Pharmaceutical had annual revenue of 378.11M, down -9.11%.
Revenue (ttm)
397.12M
Revenue Growth
+0.07%
P/S Ratio
28.45
Revenue / Employee
857.71K
Employees
463
Market Cap
11.30B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 378.11M | -37.92M | -9.11% |
| Dec 31, 2024 | 416.03M | -240.86M | -36.67% |
| Dec 31, 2023 | 656.89M | -183.76M | -21.86% |
| Jan 1, 2023 | 840.66M | 29.47M | 3.63% |
| Jan 1, 2022 | 811.18M | -66.74M | -7.60% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Nanjing Pharmaceutical Group Company | 54.56B |
| Zhejiang Int'l Group | 33.84B |
| Yifan Pharmaceutical | 5.06B |
| Zhejiang Jolly Pharmaceutical Co.,LTD | 3.11B |
| GuangYuYuan Chinese Herbal Medicine | 1.44B |
| Zhejiang Wolwo Bio-Pharmaceutical | 1.09B |
| Shanghai InnoStar Bio-tech | 812.23M |
| Chongqing Lummy Pharmaceutical | 748.94M |